DUROLANE®
hyaluronic acid, stabilized single injection

20 YEARS
DUROLANE
POWERFUL &
LONG-LASTING
PAIN RELIEF

Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (DUROLANE) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients.

SUMMARY OF RESULTS

DUROLANE Durability

- A single injection of DUROLANE was shown to last up to **6-18+ months**.
- **4** repeat injections were equally durable up to **4.5 years**.

DUROLANE Longevity

- Pain relief from hyaluronic acid injections was sustained for an average **466.8 days**.

DUROLANE's Voice of the Patient*

- **76.1%** of the patient satisfaction survey participants indicated that their pain relief was sustained for between 6 to more than 18 months post-treatment.
- **65%** of the patients would recommend DUROLANE for OA.
- **65%** of patients after their first injection felt significant relief from their OA symptoms.
- **81%** of patients after their second injection felt significant relief from their OA symptoms.

*Patient experience and satisfaction survey completed by 233 study participants.

To learn more about DUROLANE, please visit our website: **DUROLANE.com** or visit **bioventusacademy.com** to view our educational webinars.

You can also access the full study by scanning the QR code at right:

DUROLANE®
hyaluronic acid, stabilized single injection

20 YEARS
DUROLANE
POWERFUL &
LONG-LASTING
PAIN RELIEF

Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (DUROLANE) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients.

Georgia Carney

Joint Health Institute – *Melbourne, Australia*

Faculty of Medicine, Dentistry and Health Sciences – *The University of Melbourne, Parkville, Victoria, Australia*

Andrew Harrison

Bioventus International – Netherlands

Jane Fitzpatrick

Joint Health Institute – *Melbourne, Australia*

Faculty of Medicine, Dentistry and Health Sciences,
The University of Melbourne – *Parkville, Australia*

Australasian College of Sport and Exercise Physicians – *Melbourne, Victoria, Australia*

Carney G, Harrison A, Fitzpatrick J. Long-term outcome measures of repeated non-animal stabilized hyaluronic acid (Durolane) injections in osteoarthritis: a 6-year cohort study with 623 consecutive patients. *Open Access Rheumatol*. 2021;13:285-92. doi:10.2147/OARRR.S331562

STUDY PURPOSE

To determine the duration of symptom relief following repeated administration of intra-articular hyaluronic acid (HA) injections for osteoarthritis (OA)

PRIMARY OUTCOME

Length of symptom relief following repeated administration of DUROLANE HA injections for OA.

SECONDARY OUTCOME

To determine patient satisfaction with the procedure.

REFERENCE: Carney G, Harrison A,** Fitzpatrick J.** Long-term outcome measures of repeated non-animal stabilized hyaluronic acid (Durolane) injections in osteoarthritis: a 6-year cohort study with 623 consecutive patients. *Open Access Rheumatol*.2021;13:285-92. doi:10.2147/OARRR.S331562

** AH is an employee of Bioventus. JF reports grants from Joint Health Institute Ltd, during the conduct of the study; personal fees for consultancy from Bioventus Inc, grants, personal fees, non-financial support supporting clinical trial from Zimmer Biomet and Orthocell; consulting fees from Novartis, outside the submitted work. The authors report no other conflicts of interest in this work.

DUROLANE (3 mL):

Argentina, Australia,* Brazil, Chile, Colombia, EU,* India, Jordan, New Zealand,* Russia, Switzerland,* Turkey,* United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, EU and New Zealand for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Mexico: Symptomatic treatment of mild to moderate knee osteoarthritis.

Taiwan: Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Canada*: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

*DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

bioventus®
Innovations For Active Healing